Novo Nordisk's Share Buyback: A Defensive Move Amid Market Headwinds

Novo Nordisk launches a major share buyback despite its first revenue drop in 25 years, balancing challenges with new FDA approvals for Awiqli and the pending CagriSema decision.

In a bold financial maneuver, Novo Nordisk is proceeding with a multi-billion dollar share repurchase initiative even as the pharmaceutical giant faces its first revenue decline in a quarter-century. This raises a pivotal question: is this a demonstration of underlying corporate resilience, or a necessary obligation to shareholders during a challenging phase?

The buyback program, active since February 4, 2026, authorizes the repurchase of shares worth up to 15 billion Danish kroner over a one-year span. By April 1, the company had already deployed approximately 2.59 billion kroner to buy back nearly ten million of its B-shares. These shares are currently trading well below their 50-day moving average of €37.41, a price point that underscores the persistent selling pressure on the stock.

A Pipeline Offering Potential Relief

Amid the revenue concerns, developments in Novo Nordisk's product portfolio provide a counterbalance. The U.S. Food and Drug Administration (FDA) has granted approval for Awiqli, noted as the first once-weekly basal insulin for adults with type 2 diabetes and the inaugural new basal insulin class in over twenty years. A commercial launch in the United States is scheduled for the second half of 2026.

However, a more significant potential catalyst for share price recovery is the pending regulatory decision on CagriSema. This combination therapy of cagrilintide and semaglutid for obesity treatment awaits an FDA verdict around the turn of the year 2026/2027. Market observers view this as the single most important near-term catalyst ahead of the company's Capital Markets Day in September 2026. The first concrete data reflecting the impact of current pricing pressures will be revealed when Novo Nordisk publishes its Q1 2026 results in May.

Revenue Challenges from Multiple Angles

The context surrounding the buyback decision is particularly notable. For the full year 2026, Novo Nordisk forecasts a revenue contraction of between five and thirteen percent at constant exchange rates. This downturn is primarily driven by two U.S. policy factors: the Most-Favored-Nation pricing agreement with the U.S. government and restricted Medicaid reimbursement for obesity medications.

Competitive forces are adding to the strain. Rival Eli Lilly now commands over 60% of the U.S. market for obesity drugs. In a strategic response to competition from lower-cost generics containing semaglutid, Novo Nordisk implemented price cuts of up to 48% for Wegovy and Ozempic in the Indian market at the beginning of April.